» Articles » PMID: 18452684

Sublabial Transseptal Vs Transnasal Combined Endoscopic Microsurgery in Patients with Cushing Disease and MRI-depicted Microadenomas

Overview
Journal Mayo Clin Proc
Specialty General Medicine
Date 2008 May 3
PMID 18452684
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess whether the type of surgical approach to the sella (sublabial transseptal vs transnasal) affects surgical outcome among patients with Cushing disease.

Participants And Methods: Both procedures were performed at our institution from January 1, 1995, through January 31, 2003. From a total of 106 patients with Cushing disease who had had surgery, we identified 42 adults undergoing an initial surgery, with microadenoma (<1 cm) determined by magnetic resonance imaging and a minimal follow-up of 3 months.

Results: We identified 21 patients (4 male, 17 female) for sublabial transseptal transsphenoidal microsurgery. Mean+/-SD age was 45.0+/-12.9 years (range, 27.0-69.0 years); median duration of symptoms was 2.5 years (range, 1.5-7.5 years). Median follow-up was 1.0 year (range, 0.3-11.0 years). We identified another 21 patients (5 male, 16 female) for endoscopic transsphenoidal microsurgery whose mean+/-SD age was 43.8+/-14.1 years (range, 19.0-70.0 years); median duration of symptoms was 2.4 years (range, 0.2-6.0 years). Median follow-up was 2.5 years (range, 0.3-8.7 years). Complications (cerebrospinal fluid leak and transient diabetes insipidus) and cure (86% initial cure; 76% relapse-included cure) were equivalent between the 2 procedures. However, the endoscopic approach was associated with shorter anesthesia time, less blood loss, and shorter hospital stays.

Conclusion: The endoscopic transnasal surgical approach led to shorter total anesthesia time, less blood loss, and shorter hospital stay when compared with the sublabial transseptal approach. However, we found no difference between the 2 surgical procedures with respect to cure or complications, suggesting that outcome is more closely related to the experience of the operating team.

Citing Articles

Update in Cushing disease: What the neurosurgeon has to KNOW, on behalf of the EANS skull base section.

Eulate-Beramendi S, Casajus A, Ollero L, Niemann L, Fernandez-Miranda J, Bruneau M Brain Spine. 2022; 2:100917.

PMID: 36248125 PMC: 9560580. DOI: 10.1016/j.bas.2022.100917.


Systematic review and network meta-analysis assess the comparative efficacy and safety of transsphenoidal surgery for pituitary tumor.

Dai W, Zhuang Z, Ling H, Yang Y, Hang C Neurosurg Rev. 2020; 44(1):515-527.

PMID: 32036504 DOI: 10.1007/s10143-020-01240-3.


Microscopic versus endoscopic transsphenoidal surgery in the Leiden cohort treated for Cushing's disease: surgical outcome, mortality, and complications.

Broersen L, van Haalen F, Biermasz N, Lobatto D, Verstegen M, van Furth W Orphanet J Rare Dis. 2019; 14(1):64.

PMID: 30866993 PMC: 6416951. DOI: 10.1186/s13023-019-1038-0.


Endoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a systematic review and meta-analysis.

Broersen L, Biermasz N, van Furth W, de Vries F, Verstegen M, Dekkers O Pituitary. 2018; 21(5):524-534.

PMID: 29767319 PMC: 6132967. DOI: 10.1007/s11102-018-0893-3.


A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism.

Machado M, Fragoso M, Moreira A, Boguszewski C, Vieira Neto L, Naves L Arch Endocrinol Metab. 2018; 62(1):87-105.

PMID: 29694638 PMC: 10118687. DOI: 10.20945/2359-3997000000014.